Globus Medical, Inc. (GMED)
| Market Cap | 10.14B -9.7% |
| Revenue (ttm) | 3.14B +13.4% |
| Net Income | 557.64M +31.6% |
| EPS | 4.06 +31.8% |
| Shares Out | 132.47M |
| PE Ratio | 18.84 |
| Forward PE | 14.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,660,010 |
| Open | 72.12 |
| Previous Close | 71.05 |
| Day's Range | 71.91 - 76.69 |
| 52-Week Range | 70.40 - 101.40 |
| Beta | 0.95 |
| Analysts | Buy |
| Price Target | 93.43 (+22.12%) |
| Earnings Date | Nov 5, 2026 |
About GMED
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractu... [Read more]
Financial Performance
In 2025, Globus Medical's revenue was $2.94 billion, an increase of 16.65% compared to the previous year's $2.52 billion. Earnings were $537.87 million, an increase of 422.28%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for GMED stock is "Buy." The 12-month stock price target is $93.43, which is an increase of 22.12% from the latest price.
News
Globus Medical to Participate in Jefferies Global Healthcare Conference
AUDUBON, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Jefferies Global ...
Globus Medical price target lowered to $100 from $106 at BofA
BofA lowered the firm’s price target on Globus Medical (GMED) to $100 from $106 and keeps a Buy rating on the shares following the Q3 miss.
Globus Medical price target lowered to $90 from $100 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $90 from $100 and keeps a Buy rating on the shares. Earnings per share held in…
Globus Medical price target raised to $100 from $99 at Wells Fargo
Wells Fargo raised the firm’s price target on Globus Medical (GMED) to $100 from $99 and keeps an Overweight rating on the shares. The firm notes Q3 sales missed, but…
Globus Medical price target lowered to $105 from $115 at Canaccord
Canaccord analyst Caitlin Cronin lowered the firm’s price target on Globus Medical (GMED) to $105 from $115 and keeps a Buy rating on the shares. The fim said they posted…
Globus Medical downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Vik Chopra downgraded Globus Medical (GMED) to Market Perform from Outperform with a price target of $78, down from $94. The firm wants to see clearer evidence…
Globus Medical Earnings Call Transcript: Q3 2026
Q3 revenue declined as Nevro weakness and delayed spine launches outweighed growth in enabling technologies and trauma. Record free cash flow, margin expansion and new authorizations supported capital returns, while FY26 revenue guidance was reduced and management positioned 2027 as a product-led growth year.
Globus Medical Earnings release: Q3 2026
Globus Medical released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Globus Medical Quarterly report: Q3 2026
Globus Medical has published its Q3 2026 quarterly earnings report on November 5, 2026.
Globus Medical sees FY26 non-GAAP EPS $4.95-$5.05, consensus $5.00
Lowers FY26 revenue guidance to $3.09B from $3.18B-$3.22B, consensus $3.2B.
Globus Medical increases share repurchase program by $500M
Kyle Kline, CFO, said, “Our performance reflects disciplined execution across the business, which positions us to deliver sustained earnings growth, cash generation, and enhanced shareholder returns. ...
Globus Medical reports Q3 non-GAAP EPS $1.23, consensus $1.20
Reports Q3 revenue $763.7M, consensus $792.46M. “Third quarter revenue finished at $764M, down slightly from the prior year quarter,” commented Keith Pfeil, CEO. “U.S. Spine faced difficult prior year...
Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program
AUDUBON, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the third quarter ended Septe...
Globus Medical acquires cranial neurosurgery tech firm Synaptive Medical
Globus Medical (GMED) announced that it completed the acquisition of Synaptive Medical, deepening the company’s presence in cranial neurosurgery and positioning it for further growth in this market. S...
Globus Medical to Showcase SCRIPT™ Patient-Specific Implants and New XLIF™ Prone Procedural Solution at NASS 2026
AUDUBON, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will highlight its latest spine innovations at the 4...
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
AUDUBON, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended Septembe...
Globus Medical price target lowered to $85 from $115 at RBC Capital
RBC Capital analyst Shagun Singh lowered the firm’s price target on Globus Medical (GMED) to $85 from $115 and keeps an Outperform rating on the shares as part of a…
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Globus Medical Announces CE Mark for Excelsius3D™ Imaging System
Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union
Higgs Boson Health announces it has been acquired by Globus Medical
Higgs Boson Health announced it has been acquired by Globus Medical (GMED). The Higgs Boson Health team joins Globus Medical to extend surgical intelligence beyond the operating room and across…
Globus Medical acquires Higgs Boson Health
Globus Medical (GMED) acquired Higgs Boson Health, a digital healthcare experience company based in Durham, NC and incubated out of Duke University.
Globus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions
AUDUBON, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the acquisition of Higgs Boson Health, a digital health...
Globus Medical price target raised to $85 from $80 at Stifel
Stifel raised the firm’s price target on Globus Medical (GMED) to $85 from $80 and keeps a Hold rating on the shares.
Globus Medical price target lowered to $99 from $103 at Wells Fargo
Wells Fargo lowered the firm’s price target on Globus Medical (GMED) to $99 from $103 and keeps an Overweight rating on the shares. The firm notes Q2 EPS of $1.34…
Globus Medical sees Q3 revenue $67M-$73M, consensus $70.38M
At the midpoint of this outlook, the Company anticipates 30 percent year-over-year growth with approximately $40 million from the core business and $30 million from Wuxi indie Micro. Published first…